Etid klinik pou BPCO nan Lwizyàn
9 etid pou BPCO ap chèche patisipan nan sit nan Lwizyàn.
Vil nan Lwizyàn
Tèks ofisyèl etid la (Anglè)
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Southern Clinical Research - Zachary- Site Number : 8400113, Zachary
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Care Access - Shreveport - Youree Drive- Site Number : 8400007, Shreveport
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07190222A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Zachary
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07082738A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
- GSK Investigational Site, Lake Charles
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 9, 2026 · NCT07780669A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Southern Clinical Research, LLC, Zachary
Ap rekriteFaz 2/3
Laj 35 a 80 · Tout sèks · Mizajou Aug 31, 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Lafayette
- Research Site, Monroe
- Research Site, Zachary
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Aug 26, 2026 · NCT06283966STRIVE Post-Market Registry Study
- LSU Health Shreveport, Shreveport
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT04302272eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Lake Charles
- GSK Investigational Site, Shreveport
Ap rekriteFaz 3
Laj 40 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07177339Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Baton Rouge
- GSK Investigational Site, Lafayette
- GSK Investigational Site, Shreveport
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Apr 9, 2026 · NCT06961214Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.